George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
And. Earlo out
Be nice if it pushes on from here 1.052-1.111p atm, I could not believe it was 0.75p for a while on the bid first thing
Funny how on the day you buy earl you take over the thread for 24 hours then never post again then when they spike you return to pretend you are still holding, your twitter account is embarrassing and you copy and past of holding is fake, you could have 1 share in each stock and the %'s mean nothing, show a portfolio showing how many you claim to hold in each winner...we'll not be seeing that
Hope so HOMER 🙏
Sorry, but a couple of pump-and-dump merchants won't affect the price. This is moving as it's cheap, good RNS and this is hopefully the start of the rerate. Also, N4P will be attracting the attention of some big players who will gobble us up.
Yes we both did hold stocks more 24 days, let alone 24 hours,
many many times Davy50,
good to have partners like Davy50 buying the same company as I am and Bennett.
don't forget we do actively look for other new opportunities ready to deploy our hard earned cash.
Earl and GordonBennett 2 of the worst pump and dump merchants on the LSE, have they ever held any stock more than 24 hours ?
Breakout. Watching closely as its NT to buy on a dummy trade
From the 7th December RNS….
……Whilst ‘ supplying potential collaborators with in vitro data as it is gathered.
Interesting
Yes I agree, nearly 50% up and still almost worthless. Now only 88% under. Need many many more RNSs and days like this.
Good post Brighty.
There’s a significant change in tone & frequency from N4P, it’s sounding very positive.
Good move to form a direct ‘Investor Hub’, an interactive idea to engage Investors and create a longer term mentality, there is truly significant potential from these levels.
Next few weeks or months this share will be the most sought after.
Nice to s e some positive movement here, but not nice to still be 89.70% down on my investment!
Flood doors opening Earl . 1.10 being paid again
Unfortunately not but I do browse front time to time.
Hope davey hasn’t spiked me here with his ramps
Gordonbennett
are you on Twitter?
worth bouncing off ideas
Try to switch off over the weekend Earl! My three stock at the moment are DGI and as of today COPL & N4P the latter purely to upset Davey. Hi DAVE
Gordonbennett
been looking for you over the weekend.... to give you heads up on few stocks.
well done you found one
Lets hope Nigel can pull a rabbit out of the hat for N4P shareholders.
https://www.lse.co.uk/news/n4-pharma-rises-on-successful-results-from-nuvec-administration-4zxavtayk1i05x9.html
I have gotten over excited in the past about movement in this share
that being said this RNS is the most positive since i have been here (6 years). I'm guilty of getting overly emotionally attached to investments but something has made me (and many of you) stick it out through the dark days.
i've brought my average down from 13p to 2.9p over the years so for me it won't take much to turn this around.
i hope the rest of you see some pay off for your commitments also.
fingers firmly crossed.
Spot on & as you quite rightly point out more news is expected soon. It really is going to be fascinating to watch the share price rise when the investment community finally realise what's going on here. i.e. Nuvec being comparable to Roche's Venetoclax and AZ's Gefitinib. In our sector that is big news and will be piquing the interest of R&D depts at big pharmaceutical companies (including AZ and Roche.)
Once the penny drops and due diligence kicks in about the market size for manufacturing viral vectors being currently worth $5.5 billion and expected to hit $12.8 billion by 2028 the N4P share price is going to start climbing.
It's a waiting game as N4P is at present anonymous on the investor radar. However, the rapidly changing nature of the vaccine & oncology treatment markets and the significant opportunity that this presents for siRNA delivery is clearly a massive opportunity for N4P.....
Good luck, Brighty
Hi Davey, bought some purely to annoy you!
Up 41% at 1.10p so far. Maybe - just maybe - people are catching on to the mega bounce that N4P could have from here. With a tiny MCAP N4P could soar on really good news. Don't forget that Tempest Therapeutics gained 3,973% this year on positive news so there is hope for N4P. For those that aren't aware about what happened, Tempest had a similar share price collapse to N4P's which saw it fall to approx $1 US dollar before results from its liver cancer trial were unveiled. Interestingly their MCAP had fallen similarly to N4P's. It then rose from $3 million MCAP to $130 million MCAP. We just need Nigel to keep the momentum going now with a few more updates.
A reminder that in vitro studies have demonstrated that Nuvec is already comparable to two commercially available small molecule drugs, Gefitinib and Venetoclax...
Good luck, Brighty
Earl, I was checking your posts :-))...going to pretend to still be holding this one as well lol
You will never ever learn with your impatience.
I understand why some may moan given the last 12 months but it would probably be better to focus attention & efforts on drastically lowering your averages with these low prices now on offer.